Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Prescient Therapeutics is planning a clinical trial of PTX-100 in RhoA-mutant lymphomas, a niche indication where the company could potentially conduct a pivotal study before out-licensing. It has resumed recruitment in the Phase Ib component of trials of lead anti-cancer compound PTX-200 in acute myeloid leukaemia (AML) and ovarian cancer, and is working with the FDA to recommence its Phase II breast cancer study. The company had A$6.9m cash on 30 September, sufficient to fund operations into F...
MELBOURNE, Australia--(BUSINESS WIRE)-- Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX; Prescient) announced that a pre-clinical study published in the scientific journal Nature this week indicates that Prescient’s geranylgeranyl transferase inhibitor GGTI-2418, known as PTX-100, plays a key role in mitigating a new cancer pathway discovered by Professor Michele Pagano at New York University’s Langone Medical Center, in New York. Nature is regarded as one of the world’s most cited and prestigious scientific public...
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Prescient has sharpened its focus on lead anti-cancer compound PTX-200 and plans to add a Phase Ib trial in acute myeloid leukaemia (AML) to the ongoing Phase I/II trials in breast and ovarian cancers. It has raised ~A$2m through a share purchase plan and placement, which will fund operations until 2017. We raise our valuation to A$49m (A$0.53/share), with the addition of the AML indication for PTX-200 more than offsetting the deferral of Phase 1b trials for PTX-100.
Prescient is developing two promising cancer compounds that target major tumour survival pathways. It has two Phase Ib/II trials underway, and plans to initiate three more over the next year. Recent positive results from Merck validate the mechanism of action of PTX-200, which targets Akt. Prescient requires additional funding to advance its drug development programme. Our valuation is A$36m, or A$0.62 per share (pre-funding).
Prescient acquired two promising cancer compounds that target major tumour survival pathways in 2014. The most advanced compound, PTX-200, is in Phase Ib/II trials in breast and ovarian cancers; interim data from the breast cancer study are expected in early 2016. Three additional Phase Ib/II trials are scheduled to start by June 2016, subject to funding. We value Prescient at A$35m or A$0.66 per share.
Prescient acquired two promising cancer compounds that target major tumour survival pathways in 2014. The most advanced compound, PTX-200 (previously TCN-P), is in US government-funded Phase Ib/II trials in breast and ovarian cancers; interim data from the breast cancer study are expected to report in H215. Three additional Phase Ib/II trials are scheduled to commence in H115, subject to funding. Given Prescient’s small EV, positive newsflow could offer significant upside.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.